Construction of anti-cD20scFv/CD80/CD28/zeta recombinant gene modified T cell and research on its targeting cytotoxicity / 中华血液学杂志
Chinese Journal of Hematology
;
(12): 111-114, 2007.
Article
in Chinese
| WPRIM
| ID: wpr-328364
ABSTRACT
<p><b>OBJECTIVE</b>To construct anti-CD20scFv/CD80/CD28/zeta recombinant gene modified T cells, test its effectiveness of eradicating CD20+ lymphoma cells and provide a probably new approach to tumor adoptive immunotherapy.</p><p><b>METHODS</b>CD28-zeta cDNA were amplified from vector pBULLET and inserted into pLNCX vector that contained anti-CD20scFv/CD80 gene. The recombinant vectors were transduced into PA317 cells and high titer retroviruses were obtained to infect human peripheral blood T lymphocytes. Resistant T cells were obtained by G418 selection at one week. Then transduced T lymphocytes and lymphoma cell lines Daudi Raji were cocultured. The cytotoxicity and cytokine production of transduced T cells were determined by non-radio-activation cytotoxicity assay and ELISA respectively.</p><p><b>RESULTS</b>The recombinant eukaryotic vector was constructed successfully as proved by enzyme digestion analysis and sequencing. These T cells were able to lyse CD20+ target cells and secrete high levels of IL-2 and IFN-gamma in vitro.</p><p><b>CONCLUSION</b>Recombinant gene modified T cells can be constructed successfully. It can specially kill CD20 positive lymphoma cells in vitro.</p>
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Plasmids
/
T-Lymphocytes
/
Transfection
/
Cell Line
/
Immunotherapy, Adoptive
/
B7-1 Antigen
/
CD28 Antigens
/
Antigens, CD20
/
Cytotoxicity, Immunologic
/
Allergy and Immunology
Limits:
Humans
Language:
Chinese
Journal:
Chinese Journal of Hematology
Year:
2007
Type:
Article
Similar
MEDLINE
...
LILACS
LIS